KALAMAZOO–The medical equipment maker Stryker Corp. (NYSE:SYK) announced it has completed the acquisition of United Kingdom-based Cerus Endovascular Ltd., a privately held commercial-stage medical device company engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms.
Terms of the acquisition were not immediately disclosed.
Cerus Endovascular’s CE Marked products, the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter, will expand Stryker’s current portfolio of aneurysm treatment solutions.
Technology for the endovascular treatment of aneurysms has been foundational to Stryker’s Neurovascular division and Cerus Endovascular’s portfolio will address the growing need for one-and-done intrasaccular aneurysm therapy.
Cerus Endovascular’s products will expand Stryker’s current portfolio of aneurysm treatment solutions.
“The acquisition of Cerus Endovascular is highly complementary to Stryker’s Neurovascular business, and strengthens our hemorrhagic portfolio globally,” stated Jim Marucci, president of Stryker’s nurovascular division. “We look forward to working with the Cerus team to deliver on our mission of making healthcare better. Together, we will enable physicians to treat a broader range of aneurysms.”
More at www.stryker.com.